SCHEMBL4510873

SCHEMBL4510873

CC(C)(C)OC(=O)NC1CCN(c2c(F)c(F)c(C(=O)OCc3ccccc3)c(F)c2F)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.46
CTSL P07711 2/20 0.46
CTSB P07858 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RORC P51449 3/20 0.44
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
PDE10A Q9Y233 1/20 0.43
KCNA3 P22001 1/20 0.42
BTK Q06187 1/20 0.41
HSD11B1 P28845 1/20 0.41
MAP4K4 O95819 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
CHRM4 P08173 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510870 1.00 CTSK (0.46) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL4511839 0.93 CTSL (0.42) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL4511843 0.93 CTSL (0.42) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL4514090 0.88 CTSL (0.46) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL13713200 0.85 PIM1 (0.45) CTSKKMT2AL3MBTL1PIM1PIM3
SCHEMBL13713210 0.80 PIM1 (0.41) CTSKKMT2AL3MBTL1PIM1PIM3
SCHEMBL953899 0.77 HSD11B1 (0.59) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL1971844 0.77 HSD11B1 (0.59) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL1775260 0.77 HSD11B1 (0.59) CTSKCTSLCTSBKMT2AL3MBTL1
SCHEMBL12193334 0.76 CTSL (0.53) CTSKCTSLCTSBKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582627-B2 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase WARNER-LAMBERT COMPANY (US) 2009-09-01 US disclosed
EP-1255739-B1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2008-06-11 EP disclosed
US-7094780-B1 3-aminoquinazolin-2,4-dione antibacterial agents WARNER LAMBERT COMPANY LLC (US) 2006-08-22 US disclosed
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ZOETIS WLC LLC 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ABL1, NQO2, CBR3 CTSK 646/4885CTSL 2848/4885CTSB 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.